Missouri lawmakers have reintroduced legislation to prohibit drug manufactures from denying 340B covered entities access to manufacturers’ products if the covered entity uses contract pharmacies. The language is modeled on the first-of-its kind law passed in Arkansas in 2021.
Missouri Senate Bill 26 says: “A pharmaceutical manufacturer shall not prohibit an entity from contracting or participating with an entity authorized to participate in the 340B pricing program by denying access to drugs that are manufactured by the pharmaceutical manufacturer, or by denying the entity the ability to purchase drugs at the 340B price by substituting a rebate discount.”
Missouri lawmakers have reintroduced legislation to prohibit drug manufactures from denying 340B covered entities access to manufacturers’ products if the covered entity uses contract pharmacies.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
